Commentary|Videos|October 29, 2024
The TRUST-II Study of Taletrectinib in ROS1+ Advanced NSCLC
Author(s)Benjamin Besse, MD, Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Advertisement
Episodes in this series
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.
Advertisement
Related to this article
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain
Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
3
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
4
Docirbrutinib Yields High Response Rates in MCL and CLL
5